Traitement du cancer bronchique non à petites cellules au stade avancé chez le sujet âgé

A third generation drug-based mono-chemotherapy has remained for a long time the standard of treatment of advanced-non-small-cell lung cancer in the elderly. But the superiority in terms of overall survival of a carboplatin based bitherapy versus a monotherapy in fit elderly patients has recently been demonstrated. The targeted therapies are also a real progress for some patients. The main difficulty remains to select the patients who will really benefit of these treatments. The use of a geriatric assessment is recommended in order to detect the vulnerability and the tolerance of treatments. The integration of these oncogeriatric data in decision making and in the choice of treatment is evaluated in a randomized prospective study. This is a key point to optimize the treatment of the elderly.